BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1542129)

  • 1. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
    Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
    Teicher BA; Herman TS; Hopkins RE; Menon K
    J Cancer Res Clin Oncol; 1992; 118(2):123-8. PubMed ID: 1735732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
    Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
    Herman TS; Teicher BA; Coleman CN
    Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA; Holden SA; Herman TS; Frei E
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of etanidazole with cyclophosphamide and platinum complexes.
    Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
    Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
    Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
    Teicher BA; Holden SA; al-Achi A; Herman TS
    Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV; Ji M; Bloomer WD
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):775-9. PubMed ID: 9845094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAI: effects on cytotoxic therapies in vitro and in vivo.
    Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
    Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies.
    Teicher BA; Liu SD; Liu JT; Holden SA; Herman TS
    Anticancer Res; 1993; 13(5A):1549-56. PubMed ID: 8239534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
    Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
    Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
    Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
    J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV; Ji X; Bloomer WD
    J Exp Ther Oncol; 2006; 5(4):261-72. PubMed ID: 17024967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.